S

S/B vs 7/7

Thomas et al.,45

Prior CdA/DCF Tx indicates the number of patients enrolled who had prior therapy with cladribine (CdA) and/or pentostatin (DCF). Cytopenias are considered present when patients have (1) neutrophil count <1500/mm3, (2) platelets count <100,000/mm3, or (3) Hb <11g/dl.

In Thomas et al., two of the four PRs were reported as CR-RD, meaning 1-5% hairy cells in the marrow but otherwise in CR.

Prior CdA/DCF Tx indicates the number of patients enrolled who had prior therapy with cladribine (CdA) and/or pentostatin (DCF). Cytopenias are considered present when patients have (1) neutrophil count <1500/mm3, (2) platelets count <100,000/mm3, or (3) Hb <11g/dl.

In Thomas et al., two of the four PRs were reported as CR-RD, meaning 1-5% hairy cells in the marrow but otherwise in CR.

was present in two cases and resolved in both. Circulating hairy cells were eradicated in six of the seven patients. In a phase II trial from the Scripps Clinic, of 24 patients treated with rituximab, there were 3 CRs, 3 PRs, and 2 responders relapsed at a median of 15 months.44 Higher activity was observed in a trial reported by Thomas et al., in which more than four doses were given.45 Out of 15 patients, 7 who received eight doses attained a CR, and an additional patient had a CR after 12 doses. Two patients had a PR with 4 and 12 doses, and two patients had a CR with 1-5% residual marrow infiltration after 4 and 8 doses, for an overall response rate of 80%. Preexisting cytope-nias were present in five of the eight CRs and in all seven patients not achieving a CR.

0 0

Post a comment